365 related articles for article (PubMed ID: 15384973)
1. Dose and response in haemophilia--optimization of factor replacement therapy.
Srivastava A
Br J Haematol; 2004 Oct; 127(1):12-25. PubMed ID: 15384973
[TBL] [Abstract][Full Text] [Related]
2. Dose and outcome of care in haemophilia--how do we define cost-effectiveness?
Fischer K; Van den Berg HM; Thomas R; Kumar S; Poonnoose P; Viswabandya A; Mathews V; Kavitha ML; Bhattacharji S; Srivastava A
Haemophilia; 2004 Oct; 10 Suppl 4():216-20. PubMed ID: 15479401
[TBL] [Abstract][Full Text] [Related]
3. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
[TBL] [Abstract][Full Text] [Related]
4. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
[TBL] [Abstract][Full Text] [Related]
6. Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors.
Fischer K; Valentino L; Ljung R; Blanchette V
Haemophilia; 2008 Jul; 14 Suppl 3():196-201. PubMed ID: 18510542
[TBL] [Abstract][Full Text] [Related]
7. [Home treatment in hemophilia].
Pabinger I; Niessner H; Korninger C; Nowotny C; Stain M; Kyrle PA; Lechner K
Wien Klin Wochenschr; 1987 Nov; 99(22):773-7. PubMed ID: 3124354
[TBL] [Abstract][Full Text] [Related]
8. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
9. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies.
Carcao M; Chambost H; Ljung R
Haemophilia; 2010 Mar; 16 Suppl 2():4-9. PubMed ID: 20132332
[TBL] [Abstract][Full Text] [Related]
10. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
11. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
Taki M; Shirahata A
Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
[TBL] [Abstract][Full Text] [Related]
12. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis in the haemophilia population.
Blanchette VS
Haemophilia; 2010 Jul; 16 Suppl 5():181-8. PubMed ID: 20590879
[TBL] [Abstract][Full Text] [Related]
14. [Prophylaxis in patients with haemophilia complicated by inhibitors].
Paweł Ł
Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
[TBL] [Abstract][Full Text] [Related]
15. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed.
van Dijk K; Fischer K; van der Bom JG; Grobbee DE; van den Berg HM
Haemophilia; 2005 Sep; 11(5):438-43. PubMed ID: 16128885
[TBL] [Abstract][Full Text] [Related]
16. Changing pattern of care of boys with haemophilia in western European centres.
Chambost H; Ljung R;
Haemophilia; 2005 Mar; 11(2):92-9. PubMed ID: 15810909
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of haemophilic synovitis: clinical aspects.
Hoots WK; Rodriguez N; Boggio L; Valentino LA
Haemophilia; 2007 Nov; 13 Suppl 3():4-9. PubMed ID: 17822514
[TBL] [Abstract][Full Text] [Related]
18. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting.
Björkman S; Folkesson A; Berntorp E
Haemophilia; 2007 Jan; 13(1):2-8. PubMed ID: 17212717
[TBL] [Abstract][Full Text] [Related]
19. Personalized prophylaxis.
Collins PW
Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
[TBL] [Abstract][Full Text] [Related]
20. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
